Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $641.55 million. The enterprise value is $202.88 million.
Important Dates
The next confirmed earnings date is Wednesday, February 26, 2025, after market close.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 77.76 million shares outstanding. The number of shares has increased by 18.20% in one year.
| Current Share Class | 77.76M |
| Shares Outstanding | 77.76M |
| Shares Change (YoY) | +18.20% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 80.16% |
| Float | 56.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.51 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.47, with a Debt / Equity ratio of 0.04.
| Current Ratio | 11.47 |
| Quick Ratio | 11.39 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -135.09 |
Financial Efficiency
Return on equity (ROE) is -46.28% and return on invested capital (ROIC) is -30.63%.
| Return on Equity (ROE) | -46.28% |
| Return on Assets (ROA) | -28.54% |
| Return on Invested Capital (ROIC) | -30.63% |
| Return on Capital Employed (ROCE) | -49.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 142 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.32% in the last 52 weeks. The beta is 0.78, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -59.32% |
| 50-Day Moving Average | 8.49 |
| 200-Day Moving Average | 16.48 |
| Relative Strength Index (RSI) | 47.12 |
| Average Volume (20 Days) | 1,781,752 |
Short Selling Information
The latest short interest is 8.08 million, so 10.38% of the outstanding shares have been sold short.
| Short Interest | 8.08M |
| Short Previous Month | 8.14M |
| Short % of Shares Out | 10.38% |
| Short % of Float | 14.22% |
| Short Ratio (days to cover) | 5.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -217.50M |
| Pretax Income | -181.75M |
| Net Income | -197.55M |
| EBITDA | -216.64M |
| EBIT | -217.50M |
| Earnings Per Share (EPS) | -$2.36 |
Full Income StatementBalance Sheet
The company has $455.30 million in cash and $16.63 million in debt, giving a net cash position of $438.67 million or $5.64 per share.
| Cash & Cash Equivalents | 455.30M |
| Total Debt | 16.63M |
| Net Cash | 438.67M |
| Net Cash Per Share | $5.64 |
| Equity (Book Value) | 423.77M |
| Book Value Per Share | 5.45 |
| Working Capital | 422.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$169.12 million and capital expenditures -$116,000, giving a free cash flow of -$169.24 million.
| Operating Cash Flow | -169.12M |
| Capital Expenditures | -116,000 |
| Free Cash Flow | -169.24M |
| FCF Per Share | -$2.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |